menu
Home   |   Drugs   |   Ingredients   |   Pharma Companies   |   ATC   |   ICD
Share on Facebook Tweet

Harnal D

Rating: 5 - 1 review(s)
How often in a day do you take medicine? How many times?

Harnal D uses


1  INDICATIONS AND USAGE

Harnal D® (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. Harnal D capsules are not indicated for the treatment of hypertension.

2  DOSAGE AND ADMINISTRATION

Harnal D capsules 0.4 mg once daily is recommended as the dose for the treatment of the signs and symptoms of BPH. It should be administered approximately one-half hour following the same meal each day.

For those patients who fail to respond to the 0.4 mg dose after 2 to 4 weeks of dosing, the dose of Harnal D capsules can be increased to 0.8 mg once daily. Harnal D capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [ see Warnings and Precautions (5.2) ].

If Harnal D capsules administration is discontinued or interrupted for several days at either the 0.4 mg or 0.8 mg dose, therapy should be started again with the 0.4 mg once-daily dose.

3  DOSAGE FORMS AND STRENGTHS

Capsule: 0.4 mg, olive green and orange hard gelatin, imprinted on one side with Harnal D 0.4 mg and on the other side with BI 58

4  CONTRAINDICATIONS

Harnal D capsules are contraindicated in patients known to be hypersensitive to Harnal D or any component of Harnal D capsules. Reactions have included skin rash, urticaria, pruritus, angioedema, and respiratory symptoms [ see Adverse Reactions (6.2) ].

5  WARNINGS AND PRECAUTIONS

5.1  Orthostasis

The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in Harnal D capsule-treated patients than in placebo recipients. As with other alpha adrenergic blocking agents there is a potential risk of syncope [ see Adverse Reactions (6.1) ]. Patients beginning treatment with Harnal D capsules should be cautioned to avoid situations in which injury could result should syncope occur [ see Patient Counseling Information (17.1) ].

5.2  Drug Interactions

Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6. Harnal D capsules 0.4 mg should not be used in combination with strong inhibitors of CYP3A4 [ see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ]. Harnal D capsules should be used with caution in combination with moderate inhibitors of CYP3A4 (e.g., erythromycin), in combination with strong (e.g., paroxetine) or moderate (e.g., terbinafine) inhibitors of CYP2D6, in patients known to be CYP2D6 poor metabolizers particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [ see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].

Harnal D capsules should be used with caution in combination with cimetidine, particularly at a dose higher than 0.4 mg (e.g., 0.8 mg) [ see Drug Interactions (7.1) and Clinical Pharmacology (12.3) ].

Harnal D capsules should not be used in combination with other alpha adrenergic blocking agents [ see Drug Interactions (7.2) and Clinical Pharmacology (12.3) ].

Caution is advised when alpha adrenergic blocking agents including Harnal D are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [ see Drug Interactions (7.3) and Clinical Pharmacology (12.3) ].

Caution should be exercised with concomitant administration of warfarin and Harnal D capsules [ see Drug Interactions (7.4) and Clinical Pharmacology (12.3) ].

5.3  Priapism

Rarely (probably less than 1 in 50,000 patients), tamsulosin, like other alpha1 antagonists, has been associated with priapism (persistent painful penile erection unrelated to sexual activity). Because this condition can lead to permanent impotence if not properly treated, patients must be advised about the seriousness of the condition [ see Patient Counseling Information (17.2) ].

5.4  Screening for Prostate Cancer

Prostate cancer and BPH frequently co-exist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with Harnal D capsules and at regular intervals afterwards [ see Patient Counseling Information ].

5.5  Intraoperative Floppy Iris Syndrome

Intraoperative Floppy Iris Syndrome (IFIS) has been observed during cataract surgery in some patients on or previously treated with alpha1 blockers, including Harnal D capsules [ see Adverse Reactions (6.2) ].

Most reports were in patients taking the alpha1 blocker when IFIS occurred, but in some cases, the alpha1 blocker had been stopped prior to surgery. In most of these cases, the alpha1 blocker had been stopped recently prior to surgery (2 to 14 days), but in a few cases, IFIS was reported after the patient had been off the alpha1 blocker for a longer period (5 weeks to 9 months). IFIS is a variant of small pupil syndrome and is characterized by the combination of a flaccid iris that billows in response to intraoperative irrigation currents, progressive intraoperative miosis despite preoperative dilation with standard mydriatic drugs and potential prolapse of the iris toward the phacoemulsification incisions. The patient's ophthalmologist should be prepared for possible modifications to their surgical technique, such as the utilization of iris hooks, iris dilator rings, or viscoelastic substances.

IFIS may increase the risk of eye complications during and after the operation. The benefit of stopping alpha1 blocker therapy prior to cataract surgery has not been established. The initiation of therapy with tamsulosin in patients for whom cataract surgery is scheduled is not recommended.

5.6  Sulfa Allergy

In patients with sulfa allergy, allergic reaction to Harnal D capsules has been rarely reported. If a patient reports a serious or life-threatening sulfa allergy, caution is warranted when administering Harnal D capsules.

6  ADVERSE REACTIONS

To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or (800) 459-9906 TTY, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

6.1  Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reactions rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

The incidence of treatment-emergent adverse events has been ascertained from six short-term U.S. and European placebo-controlled clinical trials in which daily doses of 0.1 to 0.8 mg Harnal D capsules were used. These studies evaluated safety in 1783 patients treated with Harnal D capsules and 798 patients administered placebo. Table 1 summarizes the treatment-emergent adverse events that occurred in ≥2% of patients receiving either Harnal D capsules 0.4 mg or 0.8 mg and at an incidence numerically higher than that in the placebo group during two 13-week U.S. trials (US92-03A and US93-01) conducted in 1487 men.

BODY SYSTEM/

ADVERSE EVENT

Harnal D CAPSULES GROUPS PLACEBO
0.4 mg

n=502

0.8 mg

n=492

n=493
1 A treatment-emergent adverse event was defined as any event satisfying one of the following criteria:
  • The adverse event occurred for the first time after initial dosing with double-blind study medication.
  • The adverse event was present prior to or at the time of initial dosing with double-blind study medication and subsequently increased in severity during double-blind treatment; or
  • The adverse event was present prior to or at the time of initial dosing with double-blind study medication, disappeared completely, and then reappeared during double-blind treatment.
2 Coding preferred terms also include cold, common cold, head cold, flu, and flu-like symptoms.
3 Coding preferred terms also include nasal congestion, stuffy nose, runny nose, sinus congestion, and hay fever.
BODY AS WHOLE
Headache 97 (19.3%) 104 (21.1%) 99 (20.1%)
Infection2 45 (9.0%) 53 (10.8%) 37 (7.5%)
Asthenia 39 (7.8%) 42 (8.5%) 27 (5.5%)
Back pain 35 (7.0%) 41 (8.3%) 27 (5.5%)
Chest pain 20 (4.0%) 20 (4.1%) 18 (3.7%)
NERVOUS SYSTEM
Dizziness 75 (14.9%) 84 (17.1%) 50 (10.1%)
Somnolence 15 (3.0%) 21 (4.3%) 8 (1.6%)
Insomnia 12 (2.4%) 7 (1.4%) 3 (0.6%)
Libido decreased 5 (1.0%) 10 (2.0%) 6 (1.2%)
RESPIRATORY SYSTEM
Rhinitis3 66 (13.1%) 88 (17.9%) 41 (8.3%)
Pharyngitis 29 (5.8%) 25 (5.1%) 23 (4.7%)
Cough increased 17 (3.4%) 22 (4.5%) 12 (2.4%)
Sinusitis 11 (2.2%) 18 (3.7%) 8 (1.6%)
DIGESTIVE SYSTEM
Diarrhea 31 (6.2%) 21 (4.3%) 22 (4.5%)
Nausea 13 (2.6%) 19 (3.9%) 16 (3.2%)
Tooth disorder 6 (1.2%) 10 (2.0%) 7 (1.4%)
UROGENITAL SYSTEM
Abnormal ejaculation 42 (8.4%) 89 (18.1%) 1 (0.2%)
SPECIAL SENSES
Blurred vision 1 (0.2%) 10 (2.0%) 2 (0.4%)

Signs and Symptoms of Orthostasis

In the two U.S. studies, symptomatic postural hypotension was reported by 0.2% of patients in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and by no patients in the placebo group. Syncope was reported by 0.2% of patients (1 of 502) in the 0.4 mg group, 0.4% of patients (2 of 492) in the 0.8 mg group, and 0.6% of patients (3 of 493) in the placebo group. Dizziness was reported by 15% of patients (75 of 502) in the 0.4 mg group, 17% of patients (84 of 492) in the 0.8 mg group, and 10% of patients (50 of 493) in the placebo group. Vertigo was reported by 0.6% of patients (3 of 502) in the 0.4 mg group, 1% of patients (5 of 492) in the 0.8 mg group, and by 0.6% of patients (3 of 493) in the placebo group.

Multiple testing for orthostatic hypotension was conducted in a number of studies. Such a test was considered positive if it met one or more of the following criteria: (1) a decrease in systolic blood pressure of ≥20 mmHg upon standing from the supine position during the orthostatic tests; (2) a decrease in diastolic blood pressure ≥10 mmHg upon standing, with the standing diastolic blood pressure <65 mmHg during the orthostatic test; (3) an increase in pulse rate of ≥20 bpm upon standing with a standing pulse rate ≥100 bpm during the orthostatic test; and (4) the presence of clinical symptoms (faintness, lightheadedness/lightheaded, dizziness, spinning sensation, vertigo, or postural hypotension) upon standing during the orthostatic test.

Following the first dose of double-blind medication in Study 1, a positive orthostatic test result at 4 hours post-dose was observed in 7% of patients (37 of 498) who received Harnal D capsules 0.4 mg once daily and in 3% of the patients (8 of 253) who received placebo. At 8 hours post-dose, a positive orthostatic test result was observed for 6% of the patients (31 of 498) who received Harnal D capsules 0.4 mg once daily and 4% (9 of 250) who received placebo (Note: patients in the 0.8 mg group received 0.4 mg once daily for the first week of Study 1).

In Studies 1 and 2, at least one positive orthostatic test result was observed during the course of these studies for 81 of the 502 patients (16%) in the Harnal D capsules 0.4 mg once-daily group, 92 of the 491 patients (19%) in the Harnal D capsules 0.8 mg once-daily group, and 54 of the 493 patients (11%) in the placebo group.

Because orthostasis was detected more frequently in Harnal D capsule-treated patients than in placebo recipients, there is a potential risk of syncope [ see Warnings and Precautions (5.1) ].

Abnormal Ejaculation

Abnormal ejaculation includes ejaculation failure, ejaculation disorder, retrograde ejaculation, and ejaculation decrease. As shown in Table 1, abnormal ejaculation was associated with Harnal D capsules administration and was dose-related in the U.S. studies. Withdrawal from these clinical studies of Harnal D capsules because of abnormal ejaculation was also dose-dependent, with 8 of 492 patients (1.6%) in the 0.8 mg group and no patients in the 0.4 mg or placebo groups discontinuing treatment due to abnormal ejaculation.

Laboratory Tests

No laboratory test interactions with Harnal D capsules are known. Treatment with Harnal D capsules for up to 12 months had no significant effect on prostate-specific antigen.

6.2  Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Harnal D capsules. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Harnal D capsules.

Allergic-type reactions such as skin rash, urticaria, pruritus, angioedema, and respiratory symptoms have been reported with positive rechallenge in some cases. Priapism has been reported rarely. Infrequent reports of dyspnea, palpitations, hypotension, atrial fibrillation, arrhythmia, tachycardia, skin desquamation including reports of Stevens-Johnson syndrome, constipation, and vomiting have been received during the postmarketing period.

During cataract surgery, a variant of small pupil syndrome known as Intraoperative Floppy Iris Syndrome (IFIS) has been reported in association with alpha1 blocker therapy [ see Warnings and Precautions (5.5) ].

7  DRUG INTERACTIONS

7.1  Cytochrome P450 Inhibition

Strong and Moderate Inhibitors of CYP3A4 or CYP2D6

Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6.

Concomitant treatment with ketoconazole resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ]. The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of Harnal D have not been evaluated [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

Concomitant treatment with paroxetine (a strong inhibitor of CYP2D6) resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ]. A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when Harnal D 0.4 mg is co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, Harnal D 0.4 mg capsules should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of Harnal D have not been evaluated [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with Harnal D capsules have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when Harnal D 0.4 mg is co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

Cimetidine

Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of Harnal D, which resulted in a moderate increase in Harnal D AUC (44%) [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

7.2  Other Alpha Adrenergic Blocking Agents

The pharmacokinetic and pharmacodynamic interactions between Harnal D capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between Harnal D capsules and other alpha adrenergic blocking agents may be expected [ see Warnings and Precautions and Clinical Pharmacology (12.3) ].

7.3  PDE5 Inhibitors

Caution is advised when alpha adrenergic blocking agents including Harnal D are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ].

7.4  Warfarin

A definitive drug-drug interaction study between Harnal D and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Caution should be exercised with concomitant administration of warfarin and Harnal D capsules [ see Warnings and Precautions and Clinical Pharmacology (12.3) ].

7.5  Nifedipine, Atenolol, Enalapril

Dosage adjustments are not necessary when Harnal D capsules are administered concomitantly with nifedipine, atenolol, or enalapril [ see Clinical Pharmacology (12.3) ].

7.6  Digoxin and Theophylline

Dosage adjustments are not necessary when a Harnal D capsule is administered concomitantly with digoxin or theophylline [ see Clinical Pharmacology ].

7.7  Furosemide

Harnal D capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in Harnal D Cmax and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the Harnal D capsules dosage [ see Clinical Pharmacology (12.3) ].

8  USE IN SPECIFIC POPULATIONS

8.1  Pregnancy

Teratogenic Effects, Pregnancy Category B.

Administration of Harnal D to pregnant female rats at dose levels up to approximately 50 times the human therapeutic AUC exposure revealed no evidence of harm to the fetus. Administration of Harnal D to pregnant rabbits at dose levels up to 50 mg/kg/day produced no evidence of fetal harm. Harnal D capsules are not indicated for use in women.

8.3  Nursing Mothers

Harnal D capsules are not indicated for use in women.

8.4  Pediatric Use

Harnal D capsules are not indicated for use in pediatric populations.

Efficacy and positive benefit/risk of Harnal D was not demonstrated in two studies conducted in patients 2 years to 16 years of age with elevated detrusor leak point pressure associated with known neurological disorder (e.g., spina bifida). Patients in both studies were treated on a weight-based mg/kg schema (0.025 mg, 0.05 mg, 0.1 mg, 0.2 mg, or 0.4 mg Harnal D) for the reduction in detrusor leak point pressure below 40 cm H2O. In a randomized, double-blind, placebo-controlled, 14-week, pharmacokinetic, safety and efficacy study in 161 patients, no statistically significant difference in the proportion of responders was observed between groups receiving Harnal D and placebo. In an open-label, 12-month safety study, 87 patients were treated with Harnal D. The most frequently reported adverse events (≥5%) from the pooled data of both studies were urinary tract infection, vomiting, pyrexia, headache, nasopharyngitis, cough, pharyngitis, influenza, diarrhea, abdominal pain, and constipation.

8.5  Geriatric Use

Of the total number of subjects (1783) in clinical studies of tamsulosin, 36% were 65 years of age and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and the other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [ see Clinical Pharmacology (12.3) ].

8.6  Renal Impairment

Patients with renal impairment do not require an adjustment in Harnal D capsules dosing. However, patients with end-stage renal disease have not been studied [ see Clinical Pharmacology (12.3) ].

8.7  Hepatic Impairment

Patients with moderate hepatic impairment do not require an adjustment in Harnal D capsules dosage. Harnal D has not been studied in patients with severe hepatic impairment [ see Clinical Pharmacology (12.3) ].

10  OVERDOSAGE

Should overdosage of Harnal D capsules lead to hypotension [ see Warnings and Precautions (5.1) and Adverse Reactions (6.1) ], support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, then administration of intravenous fluids should be considered. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Harnal D is 94% to 99% protein bound; therefore, dialysis is unlikely to be of benefit.

11  DESCRIPTION

Harnal D is an antagonist of alpha1A adrenoceptors in the prostate.

Harnal D is (-)-( R )-5-[2-[[2-( o -Ethoxyphenoxy) ethyl]amino]propyl]-2-methoxybenzenesulfonamide, monohydrochloride. Harnal D is a white crystalline powder that melts with decomposition at approximately 230°C. It is sparingly soluble in water and methanol, slightly soluble in glacial acetic acid and ethanol, and practically insoluble in ether.

The empirical formula of Harnal D is C20H28N2O5S - HCl. The molecular weight of Harnal D is 444.98. Its structural formula is:

Each Harnal D capsule for oral administration contains Harnal D 0.4 mg, and the following inactive ingredients: methacrylic acid copolymer dispersion, NF; microcrystalline cellulose, NF; triacetin, USP; calcium stearate, NF; talc, USP; FD&C blue No. 2; titanium dioxide; ferric oxide; gelatin, and trace amounts of black edible ink.

12  CLINICAL PHARMACOLOGY

12.1  Mechanism of Action

The symptoms associated with benign prostatic hyperplasia are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part, by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck leading to constriction of the bladder outlet. Smooth muscle tone is mediated by the sympathetic nervous stimulation of alpha1 adrenoceptors, which are abundant in the prostate, prostatic capsule, prostatic urethra, and bladder neck. Blockade of these adrenoceptors can cause smooth muscles in the bladder neck and prostate to relax, resulting in an improvement in urine flow rate and a reduction in symptoms of BPH.

Tamsulosin, an alpha1 adrenoceptor blocking agent, exhibits selectivity for alpha1 receptors in the human prostate. At least three discrete alpha1 adrenoceptor subtypes have been identified: alpha1A, alpha1B, and alpha1D; their distribution differs between human organs and tissue. Approximately 70% of the alpha1 receptors in the human prostate are of the alpha1A subtype.

Harnal D capsules are not intended for use as an antihypertensive drug.

12.2  Pharmacodynamics

Urologic pharmacodynamic effects have been evaluated in neurologically impaired pediatric patients and in adults with BPH [ see Use in Specific Populations (8.4) and Clinical Studies (14) ].

12.3  Pharmacokinetics

The pharmacokinetics of Harnal D have been evaluated in adult healthy volunteers and patients with BPH after single and/or multiple administration with doses ranging from 0.1 mg to 1 mg.

Absorption

Absorption of Harnal D from Harnal D capsules 0.4 mg is essentially complete following oral administration under fasting conditions. Harnal D exhibits linear kinetics following single and multiple dosing, with achievement of steady-state concentrations by the fifth day of once-a-day dosing.

Effect of Food

The time to maximum concentration (Tmax) is reached by 4 to 5 hours under fasting conditions and by 6 to 7 hours when Harnal D capsules are administered with food. Taking Harnal D capsules under fasted conditions results in a 30% increase in bioavailability (AUC) and 40% to 70% increase in peak concentrations (Cmax) compared to fed conditions (Figure 1).

Figure 1 Mean Plasma Harnal D Concentrations Following Single-Dose Administration of Harnal D Capsules 0.4 mg Under Fasted and Fed Conditions (n=8)

The effects of food on the pharmacokinetics of Harnal D are consistent regardless of whether a Harnal D capsule is taken with a light breakfast or a high-fat breakfast (Table 2).

Pharmacokinetic

Parameter

0.4 mg QD to healthy

volunteers; n=23

(age range 18-32 years)

0.8 mg QD to healthy volunteers; n=22

(age range 55-75 years)

Light

Breakfast

Fasted Light

Breakfast

High-Fat

Breakfast

Fasted
Cmin = observed minimum concentration
Cmax = observed maximum Harnal D plasma concentration
Tmax = median time-to-maximum concentration
T1/2 = observed half-life
AUCτ = area under the Harnal D plasma time curve over the dosing interval
Cmin (ng/mL) 4.0 ± 2.6 3.8 ± 2.5 12.3 ± 6.7 13.5 ± 7.6 13.3 ± 13.3
Cmax (ng/mL) 10.1 ± 4.8 17.1 ± 17.1 29.8 ± 10.3 29.1 ± 11.0 41.6 ± 15.6
Cmax/Cmin Ratio 3.1 ± 1.0 5.3 ± 2.2 2.7 ± 0.7 2.5 ± 0.8 3.6 ± 1.1
Tmax (hours) 6.0 4.0 7.0 6.6 5.0
T1/2 (hours) - - - - 14.9 ± 3.9
AUCτ (ng-hr/mL) 151 ± 81.5 199 ± 94.1 440 ± 195 449 ± 217 557 ± 257

Distribution

The mean steady-state apparent volume of distribution of Harnal D after intravenous administration to 10 healthy male adults was 16 L, which is suggestive of distribution into extracellular fluids in the body.

Harnal D is extensively bound to human plasma proteins, primarily alpha1 acid glycoprotein (AAG), with linear binding over a wide concentration range (20 to 600 ng/mL). The results of two-way in vitro studies indicate that the binding of Harnal D to human plasma proteins is not affected by amitriptyline, diclofenac, glyburide, simvastatin plus simvastatin-hydroxy acid metabolite, warfarin, diazepam, propranolol, trichlormethiazide, or chlormadinone. Likewise, Harnal D had no effect on the extent of binding of these drugs.

Metabolism

There is no enantiomeric bioconversion from Harnal D [R(-) isomer] to the S(+) isomer in humans. Harnal D is extensively metabolized by cytochrome P450 enzymes in the liver and less than 10% of the dose is excreted in urine unchanged. However, the pharmacokinetic profile of the metabolites in humans has not been established. Tamsulosin is extensively metabolized, mainly by CYP3A4 and CYP2D6 as well as via some minor participation of other CYP isoenzymes. Inhibition of hepatic drug-metabolizing enzymes may lead to increased exposure to tamsulosin [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ]. The metabolites of Harnal D undergo extensive conjugation to glucuronide or sulfate prior to renal excretion.

Incubations with human liver microsomes showed no evidence of clinically significant metabolic interactions between Harnal D and amitriptyline, albuterol (beta agonist), glyburide (glibenclamide) and finasteride (5alpha-reductase inhibitor for treatment of BPH). However, results of the in vitro testing of the Harnal D interaction with diclofenac and warfarin were equivocal.

Excretion

On administration of the radiolabeled dose of Harnal D to 4 healthy volunteers, 97% of the administered radioactivity was recovered, with urine representing the primary route of excretion compared to feces (21%) over 168 hours.

Following intravenous or oral administration of an immediate-release formulation, the elimination half-life of Harnal D in plasma ranged from 5 to 7 hours. Because of absorption rate-controlled pharmacokinetics with Harnal D capsules, the apparent half-life of Harnal D is approximately 9 to 13 hours in healthy volunteers and 14 to 15 hours in the target population.

Harnal D undergoes restrictive clearance in humans, with a relatively low systemic clearance (2.88 L/h).

Specific Populations

Pediatric Use
Harnal D capsules are not indicated for use in pediatric populations [ see Use in Specific Populations ].

Geriatric (Age) Use
Cross-study comparison of Harnal D capsules overall exposure (AUC) and half-life indicates that the pharmacokinetic disposition of Harnal D may be slightly prolonged in geriatric males compared to young, healthy male volunteers. Intrinsic clearance is independent of Harnal D binding to AAG, but diminishes with age, resulting in a 40% overall higher exposure (AUC) in subjects of age 55 to 75 years compared to subjects of age 20 to 32 years [ see Use in Specific Populations (8.5) ].

Renal Impairment
The pharmacokinetics of Harnal D have been compared in 6 subjects with mild-moderate or moderate-severe (10≤ CLcr <30 mL/min/1.73 m2) renal impairment and 6 normal subjects (CLcr >90 mL/min/1.73 m2). While a change in the overall plasma concentration of Harnal D was observed as the result of altered binding to AAG, the unbound (active) concentration of Harnal D, as well as the intrinsic clearance, remained relatively constant. Therefore, patients with renal impairment do not require an adjustment in Harnal D capsules dosing. However, patients with end-stage renal disease (CLcr <10 mL/min/1.73 m2) have not been studied [ see Use in Specific Populations (8.6) ].

Hepatic Impairment
The pharmacokinetics of Harnal D have been compared in 8 subjects with moderate hepatic impairment (Child-Pugh’s classification: Grades A and B) and 8 normal subjects. While a change in the overall plasma concentration of Harnal D was observed as the result of altered binding to AAG, the unbound (active) concentration of Harnal D does not change significantly, with only a modest (32%) change in intrinsic clearance of unbound Harnal D. Therefore, patients with moderate hepatic impairment do not require an adjustment in Harnal D capsules dosage. Harnal D has not been studied in patients with severe hepatic impairment [ see Use in Specific Populations (8.7) ].

Drug Interactions

Cytochrome P450 Inhibition
Strong and Moderate Inhibitors of CYP3A4 or CYP2D6

The effects of ketoconazole at 400 mg once daily for 5 days on the pharmacokinetics of a single Harnal D capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years). Concomitant treatment with ketoconazole resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 2.2 and 2.8, respectively [ see Warnings and Precautions (5.2) and Clinical Pharmacology (12.3) ]. The effects of concomitant administration of a moderate CYP3A4 inhibitor (e.g., erythromycin) on the pharmacokinetics of Harnal D have not been evaluated [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].

The effects of paroxetine (a strong inhibitor of CYP2D6) at 20 mg once daily for 9 days on the pharmacokinetics of a single Harnal D capsule 0.4 mg dose was investigated in 24 healthy volunteers (age range 23 to 47 years). Concomitant treatment with paroxetine resulted in an increase in the Cmax and AUC of tamsulosin by a factor of 1.3 and 1.6, respectively [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ]. A similar increase in exposure is expected in CYP2D6 poor metabolizers (PM) as compared to extensive metabolizers (EM). A fraction of the population (about 7% of Caucasians and 2% of African Americans) are CYP2D6 PMs. Since CYP2D6 PMs cannot be readily identified and the potential for significant increase in tamsulosin exposure exists when Harnal D 0.4 mg is co-administered with strong CYP3A4 inhibitors in CYP2D6 PMs, Harnal D 0.4 mg capsules should not be used in combination with strong inhibitors of CYP3A4 (e.g., ketoconazole) [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].

The effects of concomitant administration of a moderate CYP2D6 inhibitor (e.g., terbinafine) on the pharmacokinetics of Harnal D have not been evaluated [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].

The effects of co-administration of both a CYP3A4 and a CYP2D6 inhibitor with Harnal D capsules have not been evaluated. However, there is a potential for significant increase in tamsulosin exposure when Harnal D 0.4 mg is co-administered with a combination of both CYP3A4 and CYP2D6 inhibitors [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].

Cimetidine
The effects of cimetidine at the highest recommended dose (400 mg every 6 hours for 6 days) on the pharmacokinetics of a single Harnal D capsule 0.4 mg dose was investigated in 10 healthy volunteers (age range 21 to 38 years). Treatment with cimetidine resulted in a significant decrease (26%) in the clearance of Harnal D, which resulted in a moderate increase in Harnal D AUC (44%) [ see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].

Other Alpha Adrenergic Blocking Agents
The pharmacokinetic and pharmacodynamic interactions between Harnal D capsules and other alpha adrenergic blocking agents have not been determined; however, interactions between Harnal D capsules and other alpha adrenergic blocking agents may be expected [ see Warnings and Precautions and Drug Interactions (7.2) ].

PDE5 Inhibitors
Caution is advised when alpha adrenergic blocking agents, including Harnal D, are co-administered with PDE5 inhibitors. Alpha-adrenergic blockers and PDE5 inhibitors are both vasodilators that can lower blood pressure. Concomitant use of these two drug classes can potentially cause symptomatic hypotension [ see Warnings and Precautions (5.2) and Drug Interactions (7.3) ].

Warfarin
A definitive drug-drug interaction study between Harnal D and warfarin was not conducted. Results from limited in vitro and in vivo studies are inconclusive. Therefore, caution should be exercised with concomitant administration of warfarin and Harnal D capsules [ see Warnings and Precautions and Drug Interactions (7.4) ].

Nifedipine, Atenolol, Enalapril
In three studies in hypertensive subjects (age range 47 to 79 years) whose blood pressure was controlled with stable doses of nifedipine, atenolol, or enalapril for at least 3 months, Harnal D capsules 0.4 mg for 7 days followed by Harnal D capsules 0.8 mg for another 7 days (n=8 per study) resulted in no clinically significant effects on blood pressure and pulse rate compared to placebo (n=4 per study). Therefore, dosage adjustments are not necessary when Harnal D capsules are administered concomitantly with nifedipine, atenolol, or enalapril [ see Drug Interactions (7.5) ].

Digoxin and Theophylline
In two studies in healthy volunteers receiving Harnal D capsules 0.4 mg/day for 2 days, followed by Harnal D capsules 0.8 mg/day for 5 to 8 days, single intravenous doses of digoxin 0.5 mg or theophylline 5 mg/kg resulted in no change in the pharmacokinetics of digoxin or theophylline. Therefore, dosage adjustments are not necessary when a Harnal D capsule is administered concomitantly with digoxin or theophylline [ see Drug Interactions (7.6) ].

Furosemide
The pharmacokinetic and pharmacodynamic interaction between Harnal D capsules 0.8 mg/day (steady-state) and furosemide 20 mg intravenously (single dose) was evaluated in 10 healthy volunteers (age range 21 to 40 years). Harnal D capsules had no effect on the pharmacodynamics (excretion of electrolytes) of furosemide. While furosemide produced an 11% to 12% reduction in Harnal D Cmax and AUC, these changes are expected to be clinically insignificant and do not require adjustment of the Harnal D capsules dosage [ see Drug Interactions (7.7) ].

13  NONCLINICAL TOXICOLOGY

13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility

Rats administered doses up to 43 mg/kg/day in males and 52 mg/kg/day in females had no increases in tumor incidence, with the exception of a modest increase in the frequency of mammary gland fibroadenomas in female rats receiving doses ≥5.4 mg/kg (P<0.015). The highest doses of Harnal D evaluated in the rat carcinogenicity study produced systemic exposures (AUC) in rats 3 times the exposures in men receiving the maximum therapeutic dose of 0.8 mg/day.

Mice were administered doses up to 127 mg/kg/day in males and 158 mg/kg/day in females. There were no significant tumor findings in male mice. Female mice treated for 2 years with the two highest doses of 45 and 158 mg/kg/day had statistically significant increases in the incidence of mammary gland fibroadenomas (P<0.0001) and adenocarcinomas (P<0.0075). The highest dose levels of Harnal D evaluated in the mice carcinogenicity study produced systemic exposures (AUC) in mice 8 times the exposures in men receiving the maximum therapeutic dose of 0.8 mg/day.

The increased incidences of mammary gland neoplasms in female rats and mice were considered secondary to tamsulosin hydrochloride-induced hyperprolactinemia. It is not known if Harnal D capsules elevate prolactin in humans. The relevance for human risk of the findings of prolactin-mediated endocrine tumors in rodents is not known.

Harnal D produced no evidence of mutagenic potential in vitro in the Ames reverse mutation test, mouse lymphoma thymidine kinase assay, unscheduled DNA repair synthesis assay, and chromosomal aberration assays in Chinese hamster ovary cells or human lymphocytes. There were no mutagenic effects in the in vivo sister chromatid exchange and mouse micronucleus assay.

Studies in rats revealed significantly reduced fertility in males dosed with single or multiple daily doses of 300 mg/kg/day of Harnal D (AUC exposure in rats about 50 times the human exposure with the maximum therapeutic dose). The mechanism of decreased fertility in male rats is considered to be an effect of the compound on the vaginal plug formation possibly due to changes of semen content or impairment of ejaculation. The effects on fertility were reversible, showing improvement by 3 days after a single dose and 4 weeks after multiple dosing. Effects on fertility in males were completely reversed within nine weeks of discontinuation of multiple dosing. Multiple doses of 10 and 100 mg/kg/day Harnal D (1/5 and 16 times the anticipated human AUC exposure) did not significantly alter fertility in male rats. Effects of Harnal D on sperm counts or sperm function have not been evaluated.

Studies in female rats revealed significant reductions in fertility after single or multiple dosing with 300 mg/kg/day of the R-isomer or racemic mixture of Harnal D, respectively. In female rats, the reductions in fertility after single doses were considered to be associated with impairments in fertilization. Multiple dosing with 10 or 100 mg/kg/day of the racemic mixture did not significantly alter fertility in female rats.

14  CLINICAL STUDIES

Four placebo-controlled clinical studies and one active-controlled clinical study enrolled a total of 2296 patients (1003 received Harnal D capsules 0.4 mg once daily, 491 received Harnal D capsules 0.8 mg once daily, and 802 were control patients) in the U.S. and Europe.

In the two U.S. placebo-controlled, double-blind, 13-week, multicenter studies [Study 1 (US92-03A) and Study 2 (US93-01)], 1486 men with the signs and symptoms of BPH were enrolled. In both studies, patients were randomized to either placebo, Harnal D capsules 0.4 mg once daily, or Harnal D capsules 0.8 mg once daily. Patients in Harnal D capsules 0.8 mg once-daily treatment groups received a dose of 0.4 mg once daily for one week before increasing to the 0.8 mg once-daily dose. The primary efficacy assessments included: 1) total American Urological Association (AUA) Symptom Score questionnaire, which evaluated irritative (frequency, urgency, and nocturia), and obstructive (hesitancy, incomplete emptying, intermittency, and weak stream) symptoms, where a decrease in score is consistent with improvement in symptoms; and 2) peak urine flow rate, where an increased peak urine flow rate value over baseline is consistent with decreased urinary obstruction.

Mean changes from baseline to Week 13 in total AUA Symptom Score were significantly greater for groups treated with Harnal D capsules 0.4 mg and 0.8 mg once daily compared to placebo in both U.S. studies (Table 3, Figures 2A and 2B). The changes from baseline to Week 13 in peak urine flow rate were also significantly greater for the Harnal D capsules 0.4 mg and 0.8 mg once-daily groups compared to placebo in Study 1, and for the Harnal D capsules 0.8 mg once-daily group in Study 2 (Table 3, Figures 3A and 3B). Overall there were no significant differences in improvement observed in total AUA Symptom Scores or peak urine flow rates between the 0.4 mg and the 0.8 mg dose groups with the exception that the 0.8 mg dose in Study 1 had a significantly greater improvement in total AUA Symptom Score compared to the 0.4 mg dose.

Total AUA Symptom Score Peak Urine Flow Rate
Mean Baseline

Value

Mean

Change

Mean Baseline

Value

Mean

Change

* Statistically significant difference from placebo (p-value ≤0.050; Bonferroni-Holm multiple test procedure).
** Total AUA Symptom Scores ranged from 0 to 35.
† Peak urine flow rate measured 4 to 8 hours post dose at Week 13.
‡ Peak urine flow rate measured 24 to 27 hours post dose at Week 13.
Week 13: For patients not completing the 13-week study, the last observation was carried forward.
Study 1 †
Harnal D capsules

0.8 mg once daily

 19.9 ± 4.9

n=247

 -9.6* ± 6.7

n=237

 9.57 ± 2.51

n=247

 1.78* ± 3.35

n=247
Harnal D capsules

0.4 mg once daily

 19.8 ± 5.0

n=254

 -8.3* ± 6.5

n=246

 9.46 ± 2.49

n=254

 1.75* ± 3.57

n=254
Placebo 19.6 ± 4.9

n=254

 -5.5 ± 6.6

n=246

 9.75 ± 2.54

n=254

 0.52 ± 3.39

n=253
Study 2 ‡
Harnal D capsules

0.8 mg once daily

 18.2 ± 5.6

n=244

 -5.8* ± 6.4

n=238

 9.96 ± 3.16

n=244

 1.79* ± 3.36

n=237
Harnal D capsules

0.4 mg once daily

 17.9 ± 5.8

n=248

 -5.1* ± 6.4

n=244

 9.94 ± 3.14

n=248

 1.52 ± 3.64

n=244
Placebo 19.2 ± 6.0

n=239

 -3.6 ± 5.7

n=235

 9.95 ± 3.12

n=239

 0.93 ± 3.28

n=235
Mean total AUA Symptom Scores for both Harnal D capsules 0.4 mg and 0.8 mg once-daily groups showed a rapid decrease starting at 1 week after dosing and remained decreased through 13 weeks in both studies (Figures 2A and 2B).

In Study 1, 400 patients (53% of the originally randomized group) elected to continue in their originally assigned treatment groups in a double-blind, placebo-controlled, 40-week extension trial (138 patients on 0.4 mg, 135 patients on 0.8 mg, and 127 patients on placebo). Three hundred twenty-three patients (43% of the originally randomized group) completed one year. Of these, 81% (97 patients) on 0.4 mg, 74% (75 patients) on 0.8 mg, and 56% (57 patients) on placebo had a response ≥25% above baseline in total AUA Symptom Score at one year.

Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0-35) Study 1

* indicates significant difference from placebo (p-value ≤0.050).

B = Baseline determined approximately one week prior to the initial dose of double-blind medication at Week 0.

Subsequent values are observed cases.

LOCF = Last observation carried forward for patients not completing the 13-week study.

Note: Patients in the 0.8 mg treatment group received 0.4 mg for the first week.

Note: Total AUA Symptom Scores range from 0 to 35.

Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0-35) Study 2

* indicates significant difference from placebo (p-value ≤0.050).

Baseline measurement was taken Week 0. Subsequent values are observed cases.

LOCF = Last observation carried forward for patients not completing the 13-week study.

Note: Patients in the 0.8 mg treatment group received 0.4 mg for the first week.

Note: Total AUA Symptom Scores range from 0 to 35.

Figure 3A Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1

* indicates significant difference from placebo (p-value ≤0.050).

B = Baseline determined approximately one week prior to the initial dose of double-blind medication at Week 0.

Subsequent values are observed cases.

LOCF = Last observation carried forward for patients not completing the 13-week study.

Note: The uroflowmetry assessments at Week 0 were recorded 4 to 8 hours after patients received the first dose of double-blind medication.

Measurements at each visit were scheduled 4 to 8 hours after dosing (approximate peak plasma tamsulosin concentration).

Note: Patients in the 0.8 mg treatment groups received 0.4 mg for the first week.

Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2

* indicates significant difference from placebo (p-value ≤0.050).

Baseline measurement was taken Week 0. Subsequent values are observed cases.

LOCF = Last observation carried forward for patients not completing the 13-week study.

Note: Patients in the 0.8 mg treatment group received 0.4 mg for the first week.

Note: Week 1 and Week 2 measurements were scheduled 4 to 8 hours after dosing (approximate peak plasma tamsulosin concentration).

All other visits were scheduled 24 to 27 hours after dosing (approximate trough tamsulosin concentration).

16  HOW SUPPLIED/STORAGE AND HANDLING

Harnal D capsules 0.4 mg are supplied in high density polyethylene bottles containing 100 hard gelatin capsules with olive green opaque cap and orange opaque body. The capsules are imprinted on one side with Harnal D 0.4 mg and on the other side with BI 58.

Harnal D capsules 0.4 mg, 100 capsules (NDC 0597-0058-01)

Store at 25°C (77°F); excursions permitted to 15°C–30°C (59°F–86°F).

Keep Harnal D capsules and all medicines out of reach of children.

17  PATIENT COUNSELING INFORMATION

See FDA-Approved Patient Labeling.

17.1  Hypotension

Patients should be told about the possible occurrence of symptoms related to postural hypotension, such as dizziness, when taking Harnal D capsules, and they should be cautioned about driving, operating machinery, or performing hazardous tasks [ see Warnings and Precautions (5.1) ].

17.2  Priapism

Patients should be advised about the possibility of priapism as a result of treatment with Harnal D capsules and other similar medications. Patients should be informed that this reaction is extremely rare, but if not brought to immediate medical attention, can lead to permanent erectile dysfunction [ see Warnings and Precautions (5.3) ].

17.3  Screening for Prostate Cancer

Prostate cancer and BPH frequently co-exist; therefore, patients should be screened for the presence of prostate cancer prior to treatment with Harnal D capsules and at regular intervals afterwards [ see Warnings and Precautions (5.4) ].

17.4  Intraoperative Floppy Iris Syndrome

Patients considering cataract surgery should be advised to tell their ophthalmologist that they have taken Harnal D capsules [ see Warnings and Precautions ].

17.5  Administration

Patients should be advised not to crush or chew the Harnal D capsules.

Patient labeling is provided as a tear-off leaflet at the end of this prescribing information.

Distributed by:

Boehringer Ingelheim Pharmaceuticals, Inc.

Ridgefield, CT 06877 USA

Harnal D is a registered trademark of, and licensed from:

Astellas Pharma Inc.

Tokyo 103-8411, JAPAN

Copyright 2012, ALL RIGHTS RESERVED

IT8004TE082012

PRT97

PATIENT INFORMATION

Flomax® (Flō-max)

(tamsulosin hydrochloride)

Capsules, 0.4 mg

Read the Patient Information that comes with Harnal D capsules before you start taking it and each time you refill your prescription. The information may have changed. This leaflet does not take the place of discussions with your doctor about your medical condition or your treatment.

What is Harnal D?

Harnal D is a prescription alpha-blocker medicine used to treat the signs and symptoms of benign prostatic hyperplasia (BPH), a condition your doctor may refer to as an enlarged prostate.

Who should not take Harnal D?

Do not take Harnal D capsules if you are allergic to any of its ingredients. See the end of this leaflet for a complete list of ingredients in Harnal D capsules.

What should I tell my doctor before using Harnal D?

Before taking Harnal D capsules, tell your doctor about all your medical conditions, including:

Tell your doctor about all the medicines you take, including:

Some of your other medicines may affect the way Harnal D capsules work. Especially tell your doctor if you take a medicine for high blood pressure. You should not take Harnal D if you are already taking certain blood pressure medicines.

Know the medicines you take. Keep a list of them and show it to your doctor and pharmacist when you get a new medicine.

How should I take Harnal D?

What are the possible side effects of Harnal D capsules?

Possible side effects of Harnal D may include:

Common side effects of Harnal D capsules may include:

These are not all the possible side effects with Harnal D capsules. Tell your doctor if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088, or by visiting www.fda.gov/medwatch.

What should I avoid while taking Harnal D capsules?

Avoid driving, operating machinery, or other dangerous activities, until you know how Harnal D affects you. Harnal D capsules may cause a sudden drop in blood pressure upon standing, especially after the first dose or when changing doses. See " What are the possible side effects of Harnal D capsules? "

How do I store Harnal D capsules?

Store Harnal D capsules at Room Temperature [77°F (25°C)]. Short-term exposure to higher or lower temperatures [from 59°F (15°C) to 86°F (30°C)] is acceptable. Ask your doctor or pharmacist if you have any questions about storing your capsules.

Keep Harnal D capsules and all medicines out of the reach of children.

General information

This medicine was prescribed for you by your doctor for your condition. Do not use it for another condition. Do not give Harnal D to other people, even if they have the same symptoms that you have. It may harm them.

While taking Harnal D, you must have regular checkups. Follow your doctor's advice about when to have these checkups.

BPH can occur with other more serious conditions, including prostate cancer. Therefore, ask your doctor about screening for prostate cancer prior to treatment with Harnal D capsules and at regular intervals afterwards.

This patient information leaflet summarizes the most important information about Harnal D. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Harnal D that is written for health professionals. For more information call Boehringer Ingelheim Pharmaceuticals, Inc. at 1-800-542-6257, or (TTY) 1-800-459-9906.

What are the ingredients in Harnal D capsules?

Distributed by:

Boehringer Ingelheim Pharmaceuticals, Inc.

Ridgefield, CT 06877 USA

Harnal D is a registered trademark of, and licensed from:

Astellas Pharma Inc.

Tokyo 103-8411, JAPAN

Copyright 2012, ALL RIGHTS RESERVED

IT8004TE082012

PRT97

Revised: May 2012

Harnal D Structure Figure 1 Figure 2a Figure 2b Figure 3a Figure 3b

Harnal D pharmaceutical active ingredients containing related brand and generic drugs:


Harnal D available forms, composition, doses:


Harnal D destination | category:


Harnal D Anatomical Therapeutic Chemical codes:


Harnal D pharmaceutical companies:


References

  1. Dailymed."FLOMAX (TAMSULOSIN HYDROCHLORIDE) CAPSULE [BRYANT RANCH PREPACK]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
  2. "TAMSULOSIN". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
  3. "TAMSULOSIN". http://www.drugbank.ca/drugs/DB0070... (accessed August 28, 2018).

Frequently asked Questions

Can i drive or operate heavy machine after consuming Harnal D?

Depending on the reaction of the Harnal D after taken, if you are feeling dizziness, drowsiness or any weakness as a reaction on your body, Then consider Harnal D not safe to drive or operate heavy machine after consumption. Meaning that, do not drive or operate heavy duty machines after taking the capsule if the capsule has a strange reaction on your body like dizziness, drowsiness. As prescribed by a pharmacist, it is dangerous to take alcohol while taking medicines as it exposed patients to drowsiness and health risk. Please take note of such effect most especially when taking Primosa capsule. It's advisable to consult your doctor on time for a proper recommendation and medical consultations.

Is Harnal D addictive or habit forming?

Medicines are not designed with the mind of creating an addiction or abuse on the health of the users. Addictive Medicine is categorically called Controlled substances by the government. For instance, Schedule H or X in India and schedule II-V in the US are controlled substances.

Please consult the medicine instruction manual on how to use and ensure it is not a controlled substance.In conclusion, self medication is a killer to your health. Consult your doctor for a proper prescription, recommendation, and guidiance.

advertisement

Review

sdrugs.com conducted a study on Harnal D, and the result of the survey is set out below. It is noteworthy that the product of the survey is based on the perception and impressions of the visitors of the website as well as the views of Harnal D consumers. We, as a result of this, advice that you do not base your therapeutic or medical decisions on this result, but rather consult your certified medical experts for their recommendations.

Visitor reports

One visitor reported useful

How is the drug Harnal D useful in reducing or relieving the symptoms? How useful is it?
According to the survey conducted by the website sdrugs.com, there are variable results and below are the percentages of the users that say the medicine is useful to them and that say it is not helping them much. It is not ideal to continue taking the medication if you feel it is not helping you much. Contact your healthcare provider to check if there is a need to change the medicine or if there is a need to re-evaluate your condition. The usefulness of the medicine may vary from patient to patient, depending on the other diseases he is suffering from and slightly depends on the brand name.
Visitors%
Useful1
100.0%

Visitor reported side effects

No survey data has been collected yet

Visitor reported price estimates

No survey data has been collected yet

Two visitors reported frequency of use

How often in a day do you take the medicine?
Are you taking the Harnal D drug as prescribed by the doctor?
Few medications can be taken Once in a day more than prescribed when the doctor's advice mentions the medicine can be taken according to frequency or severity of symptoms. Most times, be very careful and clear about the number of times you are taking the medication. The report of sdrugs.com website users about the frequency of taking the drug Harnal D is mentioned below.
Visitors%
Once in a day2
100.0%

Visitor reported doses

No survey data has been collected yet

Three visitors reported time for results

What is the time duration Harnal D drug must be taken for it to be effective or for it to reduce the symptoms?
Most chronic conditions need at least some time so the dose and the drug action gets adjusted to the body to get the desired effect. The stastistics say sdrugs.com website users needed 1 day to notice the result from using Harnal D drug. The time needed to show improvement in health condition after using the medicine Harnal D need not be same for all the users. It varies based on other factors.
Visitors%
1 day1
33.3%
> 3 month1
33.3%
1 week1
33.3%

Visitor reported administration

No survey data has been collected yet

Three visitors reported age

Visitors%
> 603
100.0%

Visitor reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 22 here

The information was verified by Dr. Rachana Salvi, MD Pharmacology


| About | Privacy Policy
© 2002 - 2024 "sdrugs.com". All Rights Reserved